… dementia, amyotrophic lateral sclerosis, Parkinson’s disease, … of nanomedicine from bench
to bed side is also discussed. … Current medical therapies with advanced treatment modalities …

… In order to progress therapies from the bench to the bedside, biomarkers of disease that …
Encouragingly, ASO treatment of mouse models has been shown to lead to durable, decreased …

… treatment of ALS. These findings hold potential for facilitating the translation of research from
bench to bedside… Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. …

… (PD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), are incurable
… of disease monitoring and treatment. Amyotrophic lateral sclerosis affects the motor system …

Amyotrophic lateral sclerosis (ALS) is a rare, neurodegenerative motor neuron disease that
affects voluntary muscle movement. Often, difficulty in coughing, breathing, and swallowing …

… is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis
(… as an oral drug in a patient population plagued with dysphagia, and has known systemic …

… Edaravone is indicated for treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's …
Medical uses Edaravone is used to treat patients with amyotrophic lateral sclerosis (ALS), which …

… Amyotrophic lateral sclerosis (ALS) is a fatal condition characterized by the … therapies
for the definitive treatment of ALS that can stop its clinical progression. Available treatments …

… models of amyotrophic lateral sclerosis (ALS)/MND using pharmacological and genetic …
In addition, we also provide therapeutic strategies that can help treat diseases by targeting …

… treatment for ALS that can prevent neither its progression nor reverse its development. However,
there are treatments … Journal of the American Medical Association, 298(2), 207–216. doi:…